| 2021-GHOS-69206 | |
| Researchers at Purdue University have developed a new class of noncovalent functionalized bis-amide inhibitors for treatment of Covid-19. There remains an ongoing global health pandemic which has now affected over 170 million people to date and there is no available therapeutic option. The compounds developed by Purdue researchers in this disclosure are newer modified versions of bis-amide derivatives that have demonstrated potent inhibitory effect on SARS-CoV-2 enzyme, 3CLpro. These inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections. Advantages: -Potent Covid-19 Antiviral Properties -Improved Drug-Like Features Potential Applications: -Treatment of SARS-CoV-2 -Pharmaceutical Research and Development -Pandemic Control Technology Validation: The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays. |
|
|
|
|
Dec 1, 2020
Provisional-Gov. Funding
United States
(None)
(None)
(None)
PCT-Gov. Funding
WO
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |